PATIENT DEMOGRAPHICS. Surname. Given name. Pacific Islander (non-maori) ADMISSION DETAILS

Similar documents
Staphylococcus aureus and Health Care associated Infections

Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members)

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Antibiotic Usage Guidelines in Hospital

Source: Portland State University Population Research Center (

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

2010 ARO/CDI Prevalence Survey. MRSA [ ] VRE [ ] Clostridium difficile [ ]

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY

Hospital Acquired Infections in the Era of Antimicrobial Resistance

Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT

NEONATAL Point Prevalence Survey. Ward Form

2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY

Treatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals

Gram negative bacteraemia

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

Meropenem for all? Midge Asogan ICU Fellow (also ID AT)

DATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients.

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 3. Policy/Procedure/Guideline 3

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

MRSA CROSS INFECTION RISK: IS YOUR PRACTICE CLEAN ENOUGH?

Infection prevention & control update for Clinical Council

GENERAL NOTES: 2016 site of infection type of organism location of the patient

PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust

Approval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

A patient s guide to. MRSA - Methicillin Resistant Staphylococcus Aureus

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report. July December 2013 Second and Third Quarters 2014

Septicaemia Definitions 1

Surgical Cross Coder. Essential links from CPT codes to ICD-9-CM and HCPCS codes

Le infezioni di cute e tessuti molli

Who should read this document? 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version? 3

Antimicrobial Stewardship Program: Local Experience

Ca-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007

NHS Dumfries And Galloway. Surgical Prophylaxis Guidelines

National Antimicrobial Prescribing Survey

North West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families

VCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

LINEE GUIDA: VALORI E LIMITI

2015 Antibiotic Susceptibility Report

Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis

Antibiotic Prophylaxis Update

Scottish Surveillance of Healthcare Infection Programme (SSHAIP) Health Protection Scotland SSI Surveillance Protocol 7th Edition 2017 Question &

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship Report

Antimicrobial Prophylaxis in the Surgical Patient. M. J. Osgood

This survey was sent only to EIN members with a pediatric infectious diseases practice.

GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 2. Policy/Procedure/Guideline 4

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

Hand washing/hand hygiene reduces the number of microorganisms on the hands and is the most important practice to prevent the spread of infection.

Hyperlink to Guideline

MRSA in the United Kingdom status quo and future developments

Other Beta - lactam Antibiotics

St. Joseph s General Hospital Vegreville. and. Mary Immaculate Care Centre. Antimicrobial Stewardship Report

Appropriate Antimicrobial Therapy for Treatment of

SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS

Concise Antibiogram Toolkit Background

COMPLIANCE WITH THIS DOCUMENT IS MANDATORY

Who should read this document 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version 2. Policy/Procedure/Guideline 4

Misericordia Community Hospital (MCH) Antimicrobial Stewardship Report

The Three R s Rethink..Reduce..Rocephin

Role of the nurse in diagnosing infection: The right sample, every time

Full Title of Guideline. Author: Contact Name and Job Title. Division & Speciality. Review date December 2020

Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)

Disclosure. Objectives. Transitions in Care: Inpatient to Outpatient Parenteral Antibiotic Therapy 2/16/2017

Healthcare-associated infections surveillance report

GUIDE TO INFECTION CONTROL IN THE HOSPITAL

your hospitals, your health, our priority PARC (Policy Approval and Ratification Committee) STANDARD OPERATING PROCEDURE:

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Empiric therapy for severe suspected Staphylococcus aureus infection

Infection control in intensive care. Sandra Fairley Senior Nurse, Neurocritical Care

2016 Antibiotic Susceptibility Report

Staphylococcus Aureus

Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults

Rational management of community acquired infections

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Antimicrobial Susceptibility Patterns

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

So Why All the Fuss About Hand Hygiene?

Dr Steve Holden Consultant Microbiologist Nottingham University Hospitals NHS Trust

Welcome! 10/26/2015 1

Grey Nuns Community Hospital (GNCH) Antimicrobial Stewardship July December 2017

Antibiotic Prophylaxis in Adult Orthopaedic Surgery. Formulary/prescribing guideline

Today s Agenda: 9/30/14

Workplan on Antibiotic Usage Management

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

EUCAST recommended strains for internal quality control

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program

CODING GUIDELINES CODING GUIDELINES - OPCS NEW PAIR CODES...6 ERRATA...7. No. 18 May, 2006

Transcription:

Reviewer / hospital Date review started PATIENT DEMOGRAPHICS MRN DOB Sex Patient sticky label if available, else enter details here Surname Post-code Given name Australian Aborigine / TSI Middle Eastern South Asian Ethnicity East and SE Asian European (=Caucasian) Latin American African Other Unknown ethnicity Maori Pacific Islander (non-maori) ADMISSION DETAILS Date of presentation Date of separation Reason for admission Hospital 1 st pos.(+) blood culture taken Consultant at time of 1 st pos. (+) B/C For care of this S. aureus bacteremia (tick box) Was patient admitted to ICU during care of this SAB in the SHN or elsewhere (including onset of SAB in ICU)? Presented Tick box if Pvte. home / Homeless / N. home / Institution / Transfer from (circle) not admitted Separation Routine discharge / Signed out / Died in hospital / Transfer out / HITH to (circle) For another diagnosis (specify) Ward / area of 1st (+) blood culture Specialty at time of 1 st pos. (+) B/C Date of admission to ICU ISOLATE DETAILS Date of first positive blood culture Laboratory episode number Sensitivity testing Cepalothin/zolin/fox Fusidic acid Tetracycline Pristinamycin Resistant: R Ciprofloxacin Gentamicin Vancomycin Quinu/dalfopristin Intermediate: I Clindamycin/linco Methicillin Cotrimoxazole Tigecycline Sensitive: S Erythromycin Penicillin Linezolid Unknown / not tested: U Fluclox/dicloxacillin Rifampicin Nitrofurantoin Vancomycin MIC Isolate is a (circle) PSSA MSSA HA-MRSA UK-MRSA CA-MRSA h-visa VISA VRSA Date of the last positive blood culture for this episode? Was a -ve surveillance BC taken 48-96 hrs after starting effective antibiotics? Date of first -ve BC? Page 1: S. aureus bacteremia case review form HEALTHCARE ASSOCIATED INPATIENT / OUTPATIENT CASES

ACQUISITION DETAILS Primary classification (use AICA definitions, link available at www.boutlis.com) Community associated Nursing home associated HCA-inpatient HCA-outpatient, ours HCA-outpatient, other hosp HCA-outpatient, VMO / GP Maternal (transplacental) Unknown In opinion of ICP, hospital, ward, NH, location it likely originated In opinion of ICP, if health-care associated, specialty patient under at time it likely originated In opinion of ICP, if health-care associated, consultant at time it likely originated ANZCOSS HCA and community risk factors Most recently within 3 mo 6 mo 12 mo N/A Present within last 3 mo 6 mo 12 mo N/A (can indicate > 1) Hospitalisation not birth Close contact HCA MRSA Indicate with a only or U (in N/A column if unknown) Surgery Dialysis Resident in longterm care Close contact CA MRSA Intravenous drug use IVDU Device related bacteremias (tick relevant box or NOT DEVICE RELATED box) * e.g., household, institutional, work-related (e.g., HCW) contact with known colonised or infected patients NOT DEVICE RELATED IV CVC (non-dialysis) Pacemaker non-defib. Tube nasogastric Catheter peritoneal IV Peripheral line Pacemaker temp. wire Tube nephrostomy Catheter urinary (suprapubic) IV PICC Shunt CSF (central) Tube PEG feeding tube Catheter urinary (urethral) Mesh surgical Shunt CSF (epidural) Valve aortic Implantable defibrillator Implantable infusion device Implantable nerve stimulator Intra-cardiac (non-valve) Orthopedic prosthetic hip joint Orthopedic prosthetic knee joint Orthopedic prosthetic other joint Orthopedic screws and/or plates Stent biliary Stent esophageal Stent respiratory Stent urinary Valve mitral Valve pulmonary Valve tricuspid Vascular graft synthetic (e.g., gortex fistular) IV CVC (Dialysis) Orthopedic wires Stent vascular OTHER DEVICE (BELOW) Other device (specify) Page 2: IMACS S. aureus bacteremia case review form.

Most likely primary site of origin of the bacteremia (or secondary site if device-related and relevant) If device-related but no secondary site, tick here Central nervous system (includes epidural abscess) CVS pericarditis Genital tract Hepatobiliiary Lymphatic Skin / soft tissue skin and/or fascia Skin / soft tissue surgical wound CVS native AV fistula GIT abdo cavity Musculoskeletal bone Transplacental CVS endocarditis (aortic or mitral; left sided) CVS endocarditis (tricuspid or pulmonary; right) CVS intravascular other GIT alimentary tract Musculoskeletal - joint Urinary Head and neck (dental and/or oral) Head and neck (ENT) Musculoskeletal discitis Respiratory tract (e.g., pneumonia, empyema) Unknown sepsis syndrome with no focus CVS - mediastinitis Head and neck (eyes) Skin / soft tissue muscle Other factors relevant to the onset and origin of the bacteremia (Y or N in each of first 4 boxes) Was there a deep abscess at the primary site of origin? Was there an invasive procedure < 48 hrs previously related to the source (e.g., insertion of a CVC, biliary stent etc.)? If yes, name of procedure? Was the patient neutropenic at the time of diagnosis (neutrophil count < 1x10^9/L)? Was there a surgical site infection related to the source from a procedure in the previous 30 days (e.g., hip wound)? If yes, details of surgical site? CLINICAL TREATMENT AND OUTCOME What was the first date that antibiotics with activity against this type of S. aureus were commenced? Principal treatment (main agent used for definitive IV treatment of SAB, i.e., after susceptibility results): Choose one only NOT TREATED AT ALL Daptomycin Moxifloxacin Vancomycin Benzylpenicillin/Amp/Amox Dicloxacillin Piperacillin-tazobactam OTHER (specify below) Cephazolin/Cephalothin Flucloxacillin Teicoplanin Clindamycin/Lincomycin Linezolid Ticarcillin-clavulanate Co-trimoxazole (Bactrim) Meropenem / Imipenem Tigecycline Date 7 days after collection of B/C Date 30 days after collection of B/C Outcome at 7 days after collection of initial blood culture Survived Died Unable to determine Outcome at 30 days after collection of initial blood culture Survived Died Unable to determine If the patient was known to have died (even if subsequent to 30 days), what was the date of death? If the patient died, then was the cause of death (circle): Due to SAB / Contributed to by SAB / Unrelated to SAB Page 3: IMACS S. aureus bacteremia case review form.

CASE REVIEW OF RISK FACTORS AND POTENTIALLY PREVENTABLE FACTORS Comorbid conditions Indicate, or? Chronic renal disease Chronic respiratory disease Chronic steroid use Burns Diabetes Vascular disease Immunocompromised (including non-steroid drugs, e.g, chemo) Likely self-contamination (e.g., confused patients, IVDU) Previous S. aureus bacteremia with same type Relevant skin condition Other relevant condition (specify) Had this type of S. aureus been isolated before? If yes, what was the first date (use 15 th if only month is known; 1 July if only year)? Has patient been isolated and had contact precautions? If yes, had decolonisation been attempted? Yes, single room Yes, cohorted in a bay No, on general ward Complete this section only if a device, including IV, was identified as the primary cause of the bacteremia What was the device? Where was the device located? On what date was it inserted (enter unknown if not known)? Was the device, removed? If so, on what date? If the device was an IV line, what was the main indication (e.g., antibiotics, TPN, inotropes, chemo, dialysis, IV fluids)? If the device was not an IV, what was the main indication? Was the same type of S. aureus isolated from the device itself? From the site of the device? Was device left in place longer than required? Was device left in place longer than recommended? OTHER INFORMATION OF RELEVANCE TO THE CASE REVIEW Was a cardiac echocardiogram performed, if so, what type(s) and on what date(s)? Was patient referred to Unit referral / Self-referred by ID / Not referred infect. diseases (circle)? If yes, ID advice followed (circle)? Completely / Partially / Not at all / N/A Other general comments of relevance to the case review Page 4: IMACS S. aureus bacteremia case review form.

Give details of identified failures in any or multiple of the following (specify if yes; otherwise No or Unknown ) Prolonged inappropriate antibiotic use Adherence to device care policies Hand hygiene (e.g., product placement, include results of last audit) Cleaning and equipment decontamination (e.g., level of cleanliness on the ward) PPE availability on ward (comment on stocks, brackets, trolleys) and usage practices by staff Contact precautions / isolation on the ward Ward environment (e.g., amount of clutter, bed spacing) Understaffing on the ward (comment on staffing level at time of bacteremia) Staff knowledge and competency Known outbreak of this type of S. aureus on the ward Relevant surgical factors related to this or a previous admission Relevant medical factors related to this or a previous admission Other factors that may have influenced the chance of acquisition (including relevant treatment protocols) Page 5: IMACS S. aureus bacteremia case review form.

Summary and recommendations In your view, was this episode most likely Could a surgical procedure, if done earlier, prevented this infection? Preventable If so, how? Potentially preventable Unpreventable If preventable or potentially preventable, please list the most relevant factors that you would like treating team to know about and understand Could protocols or procedures be changed to prevent similar infections in the future? If so, please detail your suggestions Other comments Page 6: IMACS S. aureus bacteremia case review form.

Additional notes People who should be notified (full names and designations) include all direct-care doctors and NUM Page 7: IMACS S. aureus bacteremia case review form.